Skip to main content

Table 3 Summary of talimogene laherparepvec responses by lesion-type

From: Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

 

Overall tumor response

Overall lesion-type response

 

Any

OR

CR

Yes

n (%)

n (%)

n (%)

n (%)

Any

37 (100)

14 (37.8)

8 (21.6)

15 (40.5)

At least 1 baseline uninjected lesion

35 (100)

12 (34.3)

6 (17.1)

13 (37.1)

Baseline uninjected non-visceral only

23 (100)

10 (43.5)

5 (21.7)

11 (47.8)

At least 1 visceral lesion at baseline

12 (100)

2 (16.7)

1 (8.3)

2 (16.7)

  1. Denominator is the total number of patients in corresponding patient lesion-type subgroup
  2. Objective response (OR), and complete response (CR) as per investigator-reported responses. Overall lesion response was reported as the proportion of patients with a ≥ 30 % decrease in overall lesion burden. OR was evaluated by modified RECIST.
  3. Overall lesion type response: max decrease ≥ 30 % in overall lesion-type burden from baseline in patient lesion-type subgroup and in total tumor burden for “Any”
  4. All patients received at least one dose of talimogene laherparepvec
Back to article page